Fortrea (FTRE) Stock Forecast & Price Target

$20.89 +1.16 (+5.88%)

(As of 11/25/2024 ET)

Fortrea - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 12 Analyst Ratings

Sell
1

Hold
8

Buy
3

Based on 12 Wall Street analysts who have issued ratings for Fortrea in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 1 has given a sell rating, 8 have given a hold rating, 2 have given a buy rating, and 1 has given a strong buy rating for FTRE.

Consensus Price Target

$24.50
17.28% Upside

According to the 12 analysts' twelve-month price targets for Fortrea, the average price target is $24.50. The highest price target for FTRE is $30.00, while the lowest price target for FTRE is $20.00. The average price target represents a forecasted upside of 17.28% from the current price of $20.89.

Get the Latest News and Ratings for FTRE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Fortrea and its competitors.

FTRE Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)	1 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	7 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$24.50	$23.60	$27.20	$31.75
Forecasted Upside	17.28% Upside	36.18% Upside	20.19% Upside	-5.37% Downside
Consensus Rating	Hold	Hold	Hold	Hold

MUST-SEE: Everyone will be talking about this $2 trillion AI tech boom soon (Ad)

Amazon is making its biggest investment ever… $150 billion to be exact. And one company stands to benefit from this massive capital influx. This company could deliver a huge windfall for investors who get in before this story hits the mainstream, which could happen at any time.

Don't miss out... Click here to reveal Amazon’s Secret Partner.

FTRE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FTRE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Fortrea Stock vs. The Competition

Type	Fortrea	Medical Companies	S&P 500
Consensus Rating Score	2.25	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	17.28% Upside	17,622.81% Upside	6.37% Upside
News Sentiment Rating	Very Positive News See Recent FTRE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/11/2024	TD Cowen 4 of 5 stars		Boost Target	Hold ➝ Hold	$23.00 ➝ $25.00	+3.01%
11/11/2024	Barclays 3 of 5 stars	L. Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $25.00	+8.74%
11/11/2024	Robert W. Baird 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$28.00 ➝ $30.00	+27.66%
11/8/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform
10/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	In-Line ➝ In-Line	$22.00 ➝ $20.00	+7.70%
10/8/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$26.00 ➝ $23.00	+24.06%
MUST-SEE: Everyone will be talking about this $2 trillion AI tech boom soon (Ad) Amazon is making its biggest investment ever… $150 billion to be exact. And one company stands to benefit from this massive capital influx. This company could deliver a huge windfall for investors who get in before this story hits the mainstream, which could happen at any time. Don't miss out... Click here to reveal Amazon’s Secret Partner.
9/25/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$25.00 ➝ $21.00	-5.45%
8/20/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$28.00 ➝ $23.00	+2.72%
8/13/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underperform ➝ Underperform	$26.00 ➝ $21.00	-3.93%
8/13/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$42.00 ➝ $30.00	+44.44%
5/28/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$27.00	+5.68%
5/14/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Coldwell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:00 AM ET.

FTRE Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Fortrea is $24.50, with a high forecast of $30.00 and a low forecast of $20.00.
: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fortrea in the last year. There is currently 1 sell rating, 8 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FTRE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FTRE, but not buy additional shares or sell existing shares.
: According to analysts, Fortrea's stock has a predicted upside of 17.28% based on their 12-month stock forecasts.
: Over the previous 90 days, Fortrea's stock had 1 downgrade by analysts.
: Fortrea has been rated by research analysts at Barclays, Evercore ISI, Jefferies Financial Group, Robert W. Baird, TD Cowen, The Goldman Sachs Group, and William Blair in the past 90 days.
: Analysts like Fortrea less than other "medical" companies. The consensus rating for Fortrea is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FTRE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

MUST-SEE: Everyone will be talking about this $2 trillion AI tech boom soon (Ad)

Don't miss out... Click here to reveal Amazon’s Secret Partner.

This page (NASDAQ:FTRE) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortrea (FTRE) Stock Forecast & Price Target